Jump to content

KEYNOTE-A86 - Study


Recommended Posts

Visit  https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04956692 or call 888-577-8839 for more information

EYNOTE-A86 - Study of Pembrolizumab subcutaneous versus Pembrolizumab intravenous administered with platinum doublet chemotherapy in participants with metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) (NCT04956692)

You may be able to join this study if you have a new diagnosis of NSCLC that has spread to other parts of your body and has not yet been treated. The type of NSCLC you have can be squamous or non-squamous.

The trial drug you get will depend on which group you are in.  You have a 2 in 3 chance of being in Group A, and a 1 in 3 chance of being in Group B.

There are 2 Groups:

Group A: pembrolizumab subcutaneous (SC) with chemotherapy

Group B: pembrolizumab IV with chemotherapy

The type of chemotherapy you will get depends on the type of NSCLC you have:

·         Squamous: carboplatin with taxane (paclitaxel or nab-paclitaxel)

·         Non-squamous: pemetrexed with platinum (cisplatin or carboplatin)

You, your trial doctor, and the trial staff will know what you are getting.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.